

REMARKS

Applicants would first like to thank Examiner Ulm for the courtesy extended to attorney for Applicants, Dean L. Fanelli, in a May 20, 2004 telephone conference.

Claims 28-44 are currently pending in this application. Applicants have canceled claims 1-27 without prejudice to Applicants' right to file one or more continuing, divisional, or continuation-in-part applications. Applicants have added new claims 28-44, which correspond to original canceled claims 13-27, wherein Applicants have amended claim 13 as suggested by the Examiner in the May 20, 2004 telephone conference. Original claims 14-27 have been re-written as claims 29-44 to reflect proper dependency from new claim 28. No new matter has been introduced into this application. In view of the amendments and the following remarks, Applicants respectfully request reconsideration and reexamination of this application and timely allowance of the pending claims.

I. The Tables in the Specification have been Amended

Tables 1-6 have each been amended from single-line spacing to 1½ -line spacing in compliance with 37 C.F.R. §§ 1.52 and 1.58. Applicants have not added, deleted, or substituted any residues of any sequence listing in Tables 1-6. Applicants respectfully request that the objections to the tables be withdrawn.

II. The Rejections under 35 U.S.C. § 103(a) have been Overcome

Claims 1-27 stand rejected under 35 U.S.C. § 103(a) as allegedly obvious over Ancellin & Hla, 1999, *J. Biol. Chem.* 274:18997-19002 ("Ancellin") in view of any two or more of the following: Conway *et al.*, 2000, *J. Biol. Chem.* 275:20602-20609 ("Conway"); Schioth *et al.*, 1998, *Mol. Pharm.* 54:154-161 ("Schioth"); Wu *et al.*, 1997, *J. Biol. Chem.* 272:9037-9042 ("Wu"); Meng *et al.*, 1996, *Eur. J. Pharm.* 311:285-292 ("Meng"); Holtmann

et al., 1995, *J. Biol. Chem.* 270:14394-14398 (“Holtman”); Takagi *et al.*, 1995, *J. Biol. Chem.* 270:10072-10078 (“Takagi”); Buggy *et al.*, 1995, *J. Biol. Chem.* 270:7474-7478 (“Buggy”); Kim & Devreotes, 1994, *J. Biol. Chem.* 269:28724-28731 (“Kim”); Gether *et al.*, 1993, *J. Biol. Chem.* 268:7893-7898 (“Geethar”); and Kobilka *et al.*, 1988, *Science* 240:1310-1316 (“Kobilka”).

Applicants respectfully submit that having canceled claims 1-27 and added new claims 28-44, the rejection is now overcome. Particularly, Applicants submit that in accordance with the Examiner’s suggestions in the May 20, 2004 telephone conference and statements made in the September 26, 2003 Office Action (*i.e.*, to present novel elements of the structural configurations of the chimeric Edg receptors in the claim; *see* pages 7-8 of the September 26, 2003 Office Action), the claims are now in condition for allowance.


III. Conclusion

Respectfully, Applicants submit that the claims in the application are allowable. Favorable consideration and a Notice of Allowance are earnestly solicited.

Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17, which may be required, to our Deposit Account No. 50-0310.

The Examiner is invited to telephone the undersigned should he find that an interview or further discussion might advance the examination of this application.

Respectfully submitted

A handwritten signature in black ink, appearing to read 'D. L. Fanelli', written over a horizontal line.

Dean L. Fanelli
Reg. No. 48,907

Date: October 26, 2004

MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
(202) 739-3000
Customer Number 09629